Recent evidence suggests that the GluN2B subunit plays a crucial role in the molecular mechanisms underlying Parkinson’s disease, opening up the possibility of GluN2B-selective antagonists as potential therapeutic options for treating neurodegenerative disorders [153]. Here, GRIN2B is linked to Parkinson disease.